EQ504 enters Phase 1 in ulcerative colitis; the thesis hinges on whether proof-of-mechanism data justifies continued clinical investment in a crowded field

Equillium is a clinical-stage company developing a small-molecule immunomodulator for moderately to severely active ulcerative colitis, which is not yet approved.

EQ504 is a small-molecule immunomodulator in preclinical-to-Phase 1 transition targeting moderately to severely active ulcerative colitis. The thesis works only if Phase 1 proof-of-mechanism data demonstrates sufficient biological and clinical signal to warrant advancement against a competitive field. The primary risks are clinical-stage attrition at the earliest human data point and displacement by approved or late-stage oral agents such as ozanimod, etrasimod, and ABIVAX's obefazimod.